Targeted Therapy for Advanced Basal-cell Carcinoma: Vismodegib and Beyond

Overview

Journal Dermatol Ther (Heidelb)

Date 2013 Jul 27

PMID 23888252

Citations 7

Authors

C Lance Cowey

Affiliations

Soon will be listed here.

Abstract

Basal-cell carcinoma is a commonly occurring skin malignancy that has the potential to progress into locally invasive or resistant disease, as well as spread distantly. Due to advances in the molecular understanding of the disease over the last two decades, it has been discovered that the Hedgehog pathway plays an important role in the pathogenesis of this disease and can be exploited as a treatment target. Several agents that inhibit the Hedgehog pathway have reached clinical studies and one drug, vismodegib, has recently been US Food and Drug Administration (FDA) approved based on clinical activity and tolerability in patients with advanced basal-cell carcinoma. This review will describe the clinical development of vismodegib, as well as the proper application of the drug in clinical practice. Other important clinical questions, such as mechanisms of resistance to vismodegib and the role of other Hedgehog pathway inhibitors currently in development will also be discussed.

Citing Articles

Case report: Sequential treatment strategy for advanced basal cell carcinoma in Gorlin-Goltz syndrome: integration of vismodegib, radiotherapy, surgery, and high-intensity focused ultrasound.

Calik J, Oslizlo M, Slocka-Romaniuk B, Elsaftawy A, Sauer N Front Oncol. 2024; 14:1428702.

PMID: 39091908 PMC: 11291366. DOI: 10.3389/fonc.2024.1428702.

Advances in Targeting Cutaneous Melanoma.

Kasakovski D, Skrygan M, Gambichler T, Susok L Cancers (Basel). 2021; 13(9).

PMID: 33925915 PMC: 8123429. DOI: 10.3390/cancers13092090.

Vismodegib: A Review in Advanced Basal Cell Carcinoma.

Frampton J, Basset-Seguin N Drugs. 2018; 78(11):1145-1156.

PMID: 30030732 DOI: 10.1007/s40265-018-0948-9.

Nonsyndromic Multiple Basal Cell Carcinomas.

Kim D, Ko H, Jun Y Arch Craniofac Surg. 2017; 18(3):191-196.

PMID: 29090201 PMC: 5647844. DOI: 10.7181/acfs.2017.18.3.191.

Enhanced skin delivery of vismodegib by microneedle treatment.

Nguyen H, Banga A Drug Deliv Transl Res. 2015; 5(4):407-23.

PMID: 26069156 DOI: 10.1007/s13346-015-0241-3.

References

Tang J, Mackay-Wiggan J, Aszterbaum M, Yauch R, Lindgren J, Chang K . Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012; 366(23):2180-8. PMC: 4362529. DOI: 10.1056/NEJMoa1113538. View

Wadhera A, Fazio M, Bricca G, Stanton O . Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data?. Dermatol Online J. 2006; 12(5):7. View

Skvara H, Kalthoff F, Meingassner J, Wolff-Winiski B, Aschauer H, Kelleher J . Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol. 2011; 131(8):1735-44. DOI: 10.1038/jid.2011.48. View

Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A . Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med. 2010; 2(51):51ra70. PMC: 3422576. DOI: 10.1126/scitranslmed.3001599. View

Krauss S, Concordet J, Ingham P . A functionally conserved homolog of the Drosophila segment polarity gene hh is expressed in tissues with polarizing activity in zebrafish embryos. Cell. 1993; 75(7):1431-44. DOI: 10.1016/0092-8674(93)90628-4. View

Adolphe C, Hetherington R, Ellis T, Wainwright B . Patched1 functions as a gatekeeper by promoting cell cycle progression. Cancer Res. 2006; 66(4):2081-8. DOI: 10.1158/0008-5472.CAN-05-2146. View

Echelard Y, Epstein D, St-Jacques B, Shen L, Mohler J, McMahon J . Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. Cell. 1993; 75(7):1417-30. DOI: 10.1016/0092-8674(93)90627-3. View

Jemec G, Holm E . Nonmelanoma skin cancer in organ transplant patients. Transplantation. 2003; 75(3):253-7. DOI: 10.1097/01.TP.0000044135.92850.75. View

Gallagher R, Hill G, Bajdik C, Fincham S, Coldman A, McLean D . Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol. 1995; 131(2):157-63. View

10.

Velcheti V . Hedgehog signaling is a potent regulator of angiogenesis in small cell lung cancer. Med Hypotheses. 2007; 69(4):948-9. DOI: 10.1016/j.mehy.2007.02.021. View

11.

Von Hoff D, LoRusso P, Rudin C, Reddy J, Yauch R, Tibes R . Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009; 361(12):1164-72. DOI: 10.1056/NEJMoa0905360. View

12.

Chang A, Oro A . Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma. Arch Dermatol. 2012; 148(11):1324-5. PMC: 3777384. DOI: 10.1001/archdermatol.2012.2354. View

13.

Lee S, Moskowitz M, Sims J . Sonic hedgehog inversely regulates the expression of angiopoietin-1 and angiopoietin-2 in fibroblasts. Int J Mol Med. 2007; 19(3):445-51. View

14.

Yauch R, Dijkgraaf G, Alicke B, Januario T, Ahn C, Holcomb T . Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009; 326(5952):572-4. PMC: 5310713. DOI: 10.1126/science.1179386. View

15.

Gailani M, Leffell D, Glynn M, Zaphiropoulos P, Pressman C, Unden A . The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet. 1996; 14(1):78-81. DOI: 10.1038/ng0996-78. View

16.

Athar M, Li C, Tang X, Chi S, Zhang X, Kim A . Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res. 2004; 64(20):7545-52. DOI: 10.1158/0008-5472.CAN-04-1393. View

17.

Hahn H, Wicking C, Zaphiropoulous P, Gailani M, Shanley S, Chidambaram A . Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996; 85(6):841-51. DOI: 10.1016/s0092-8674(00)81268-4. View

18.

Jones E, Sajid M, Shenton A, Evans D . Basal cell carcinomas in gorlin syndrome: a review of 202 patients. J Skin Cancer. 2010; 2011:217378. PMC: 2998699. DOI: 10.1155/2011/217378. View

19.

Pan S, Wu X, Jiang J, Gao W, Wan Y, Cheng D . Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist. ACS Med Chem Lett. 2014; 1(3):130-4. PMC: 4007689. DOI: 10.1021/ml1000307. View

20.

Lauth M, Bergstrom A, Shimokawa T, Toftgard R . Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci U S A. 2007; 104(20):8455-60. PMC: 1866313. DOI: 10.1073/pnas.0609699104. View